CytoDyn to Hold Webcast to Provide a Quarterly Company Update
22 juin 2022 08h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, June 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...
CytoDyn Announces Resolution of Legal Dispute with Former Chief Medical Officer
23 mai 2022 08h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, May 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific Advisor
13 mai 2022 08h00 HE
|
CytoDyn Inc.
VANCOUVER, Washington, May 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential...
CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species”
12 avr. 2022 08h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, April 12, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program
30 mars 2022 17h00 HE
|
CytoDyn Inc.
Live webcast to be held March 31 discussing announcement VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage...
CytoDyn to Hold Webcast to Provide Company Update
30 mars 2022 08h30 HE
|
CytoDyn Inc.
VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with...
CytoDyn to Hold Webcast and Live Q/A on January 13
11 janv. 2022 16h35 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Jan. 11, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...
CytoDyn to Hold Webcast and Live Q/A on December 14
10 déc. 2021 15h59 HE
|
CytoDyn Inc.
VANCOUVER, Washington, Dec. 10, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...
CytoDyn Reminds Stockholders to Register 24 hours before November 24th Annual Meeting
16 nov. 2021 14h00 HE
|
CytoDyn Inc.
Management Team Will Present on Company’s Strategy Going Forward VANCOUVER, Washington, Nov. 16, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage...
CytoDyn Submits the First of Three Main Sections of HIV BLA to FDA Under Previously Authorized Rolling Review
16 nov. 2021 06h00 HE
|
CytoDyn Inc.
Second portion out of three major portions of BLA (CMC portion) will be submitted shortly Clinical section (last portion to complete BLA) expected to be submitted during Q1 2022 VANCOUVER,...